Abstract
BackgroundLUNAR, a randomized controlled trial, investigated the addition of rituximab (RTX) to standard of care for the treatment of lupus nephritis (LN). While this study did not meet its primary...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
